Skip to main content

Press releases 2011

2011-12-22
Moberg Derma AB (STO: MOB) and Medical Futures Inc. have agreed that the distribution agreement between the parties shall cease, and that cooperation ends. The agreement gave the distributor the exclusive right to market and sell Emtrix® in Canada.
2011-12-09
Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.
2011-11-30
Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.
2011-11-15
Moberg Derma AB (OMX: MOB) has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. The goal of the Vinnova funding is that small and medium-sized enterprises will increase their competitiveness and growth by investing in research and development and thus contribute to growth in Sweden.
2011-10-28
First profitable quarter and licensing agreement with Meda
2011-10-28
First profitable quarter and licensing agreement with Meda
2011-10-27
Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company’s criteria.
2011-09-19
Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply responsibility. Over the past year, Meda has made Nalox® market leader in the Nordic region.
2011-09-12
Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.
2011-08-10
The public company Moberg Derma AB (publ.) has through its U.S. distributor Alterna LLC received a first order from the world’s largest retail chain, Walmart, for Emtrix® – its treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.  Emtrix® will be marketed under Alterna’s well established foot care brand Kerasal® and will be named Kerasal® Nail.
2011-07-11
Moberg Derma AB (publ.) and Alterna LLC have entered into a distribution and cooperation agreement for Emtrix® – a treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.  Under the agreement Alterna receives exclusive rights to sell Emtrix® in the U.S. and assumes responsibility for sales and marketing activities.  Moberg Derma assumes production and supply responsibility. The agreement also includes co-funding of marketing activities and a net income-sharing mechanism.
2011-06-30
The number of shares and the number of votes in Moberg Derma AB (publ) have changed as a result of a new issue of 2,550,524 shares in total, in connection with Moberg Derma's listing on NASDAQ OMX Stockholm.
2011-06-10
Moberg Derma AB (publ.) today announced that CE mark has been granted for Kaprolac Skin Repair & Hydration, a product designed to treat atopic eczema and dry skin. This CE mark provides authorization to market and sell the product in the EU/EEA.
2011-06-08
Moberg Derma AB (publ.) has entered into a distribution agreement with OzHealth Pharma for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement OzHealth Pharma is granted exclusive rights to market and sell Emtrix® in Australia and New Zealand.
2011-05-20
The public offer to acquire shares in Moberg Derma AB (publ) attracted large interest and the offer was oversubscribed. Through this new share issue Moberg Derma has raised SEK 74 million before issue expenses. May 26th, 2011 will be the first day of trading on the main market of NASDAQ OMX Stockholm (Ticker symbol: MOB). The Board of Moberg Derma has taken a decision on the allotment of shares.
2011-05-02
The Board of Directors of Moberg Derma AB (publ) has applied for a listing of its shares on NASDAQ OMX Stockholm, the main list. In connection with the listing, Moberg Derma will broaden its ownership base through a new issue of SEK 74m.
2011-04-19
On April 18, 2011 was the Annual General Meeting of Moberg Derma AB (publ). In all suggestions the meeting decided in accordance with the proposal.
2011-03-29
Moberg Derma AB (publ) has entered into a letter of intent for distribution in the United States. The letter of intent includes Emtrix® – a product for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. The intention is to give the distributor an exclusive right to market and sell Emtrix® in the U.S.
2011-03-23
  Moberg Derma AB (publ) has completed the rights issue to existing shareholders decided on 24 February 2011. The new issue provides the company with MSEK 12.0.
2011-03-15
Moberg Derma AB (publ) has entered into distribution agreements with AG Farma S.A. in Spain and HairXpertise Ltd in UK for Emtrix® – for treatment of discolored and deformed nails resulting from fungal infection (onychomycosis) or psoriasis. Under the agreements, the distributors are granted exclusive rights to market and sell Emtrix®.
2011-02-02
Moberg Derma AB today reports positive results from a clinical trial of Emtrix. The trial included 75 patients with nail fungus (onychomycosis) and the results showed that 92% of the patients improved after 8 weeks of treatment. Already after 2 weeks, 77% of the patients were improved.